Since the role of MEF2 is well established in transcriptional activation that drives adverse cardiac remodeling, our findings reveal a yet unrecognized link between myocardial inflammation and adverse remodeling leading to heart failure and unmask potential new drug targets in the setting of inflammatory cardiomyopathies. Here, MEF2A is linked to heart failure.